Hugues Malonne’s Post

Everyone is talking about the Draghi report. ❓But do you know what it really says? ❓What recommendations does it make for the pharmaceutical sector and why? Everyone is looking at the new EU Commission and the mandate given for 2024-2029. ❓But what does it say about Europe's ambition for the life science sector, what does it take to become more competitive to be first in research for new treatments benefiting patients in Europe? ❓How will artificial intelligence affect health research? EFPIA - European Federation of Pharmaceutical Industries and Associations invites you to participate and discuss how to „IMAGINE a healthier, more competitive Europe” at its annual conference on 10 Decmber 2024, 14:30-18:00. Have a look at the program and confirmed speakers. Registration is mandatory, whether you want to attend in person or online. https://lnkd.in/e4pS3XRd

📢 The Access to Medicine Index 2024 has just been released🎉 🧪Pharmaceutical innovations can save lives, but access is not guaranteed for all, especially in low- and middle-income countries🌍. 📄#ATMI24 evaluates 20 leading pharmaceutical companies on their efforts to expand access to their products in LMICs. It shows uneven progress, with many patients in LMICs still lacking access to essential medicines. 🎯The report identified key initiatives undertaken by pharmaceutical companies to support access to medicines in LMICs, but also identified notable gaps, particularly in addressing non-communicable diseases. 🫱🏽🫲🏾Some of these gaps could be addressed through partnerships with organisations like MPP. 🚀MPP plays a crucial role by facilitating voluntary licensing and technology transfer to make life-saving therapies more accessible and affordable. 📄 Access the full report: https://bit.ly/3YO9sKk #Access2Meds #GlobalHealth Access to Medicine Foundation

Today, EuropaBio - the European Association for Bioindustries along with other industry associations of the HTA Stakeholder Network, published a joint industry statement addressing the EU HTA Joint Clinical Assessment Implementing Act.   📢 EuropaBio reemphasises the potential risks to #patientaccess of health #biotech innovation and reinforces concerns over the workability of the proposed draft rules, that risk creating an unworkable framework for Joint Clinical Assessments. The draft rules risk duplication of work, delays and potential wasted resources. Furthermore, the lack of involvement of developers earlier in the process may hinder the abilities of these developers to deliver on the aims of the Regulation.   EuropaBio and the HTA stakeholders remain committed to ensuring the HTA Regulation can meet its objectives and urge Member States’ representatives to take into account these serious concerns from the innovative life science #industry. ➡ Read the full statement here https://lnkd.in/eQyUSB-C Alliance for Regenerative Medicine, EFPIA - European Federation of Pharmaceutical Industries and Associations, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Vaccines Europe

Healixia and Nederlandse Vereniging voor Farmaceutische Geneeskunde (NVFG) collaborated on a survey, the first of its kind, unveiling the landscape of Medical Affairs in the BeNeLux with 118 professionals contributing their insights. During a jointly organised webinar on February 29th, NVFG and Healixia presented the key findings of the survey, underscoring the pivotal role of Medical Affairs in pharmaceutical companies and its evolution from a supportive function to a more strategic role. Speakers of this webinar were: Maaike Addicks, MD (NVFG) Corrie Kroeze (NVFG) Erik Present (Healixia) Koen Raeymaekers (Healixia) The recordings of this webinar are now available for viewing via: https://lnkd.in/eF2MY2Rz In addition to the webinar recordings, we're excited to share an insightful article delving into the intricacies of "Unveiling the Landscape of Medical Affairs in the BeNeLux." #MedicalAffairs #Benelux #HealthcareInnovation #WebinarRecordings #StayInformed #NVFG #Healixia

I can recommend to read this paper!! One of the findings was the difference between MSLs and Medical advisors in having quantative and/or qualitative KPIs. MSLs have more emphasis on quantitative KPIs. Do you use qualitative KPIs in your team? And if so can you share?

📄 NEW REPORT: Enhancing the role of UK medicine regulation We were delighted to act as research partners for a new report authored by the The Association of the British Pharmaceutical Industry (ABPI). It explores the crucial role of regulatory excellence in driving innovation and early access, supporting patient trust, and attracting investment into the UK. The report sets out key recommendations to rebuild the UK’s world-class reputation in regulatory science, medicines’ development and licensing. Stephen Adams said of the report: “The question of how to renew the operating capabilities of the MHRA is a once-in-a-generation regulatory policy challenge for life sciences in UK. GC was delighted to be asked to partner with the ABPI in producing a robust evidence base for both a clear diagnostic and a set of practical and realistic recommendations. Our consultant team was able to work alongside ABPI and UK sectoral experts to bring UK and international regulatory expertise and effective survey and stakeholder engagement techniques. The resulting report is a model of its kind”. We've linked the report in the comments 👇

The IFPMA Decision-making Framework is a very helpful tool based on the IFPMA Ethos. 👍

📢 Next week our colleague Dr. Seán Byrne will speak on the Office of Health Economics panel 'Drug Shortages: What are the causes, consequences and pathways to a solution?'. 📅 Join the discussion on Tuesday, 24th September from 16-17.00 CEST. 👉 All information and registration here -> <https://lnkd.in/eZzYuCve> During the webinar the expert panel will discuss: 🔸The root causes and costs of drug shortages, and their far-reaching consequences; 🔸International government policy measures aimed at ensuring a sustainable and resilient medicine supply; 🔸The shift from managing drug shortages to preventing them altogether. #DrugShortagesCrisis #HealthcareResilience #GlobalMedicineSupply #PreventDrugShortages #SustainablePharma #MedicineAccessForAll #PolicyForDrugSupply #PharmaSupplyChain #TacklingDrugShortages #PreventiveHealthcarePolicies

It is my best opportunity to share my acquaintance with everyone here that I was delighted to attend the FIP digital event by the International pharmaceutical Federation. The theme was "The patient Voice in Generic Medicine Development" which was conducted on 15th November 2022. The objective of the event was: 1. The FDA's perspective on a patient's role in Drug Development. 2. How the Office of Generic (OGD) Drug is working on Patients engagement. # FDA has a wise perspective on a patient's role in drug development. They have organized : * FDA patient representative program * FDA patient listening session * CDER patient focused drug development * Patient Engagement Collaborative OGD patient focused initiatives: 1. OGD focuses on patient accessibility and affordability of medication. 2. Prioritizing beyond the first generic helps drive down the cost of treatment. 3. Prioritizing the assessment of other key drug products such as those in shortage or supporting a public health emergency.

80% of the global population in low- and middle-income countries (#LMICs) faces significant barriers in accessing essential healthcare products - but access alone is not enough. The real challenge lies in ensuring those medicines reach patients who need them most. After all, expanding access has little meaning if it doesn’t create real impact for underserved communities. Discover more tomorrow with the launch of our 2024 Access to Medicine Index #ATMI24.